# ATP6AP2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ATP6AP2 encodes a type I transmembrane protein with dual roles: a receptor for renin/prorenin and an obligate accessory subunit of the vacuolar H⁺-ATPase (V-ATPase), crucial for lysosomal and endosomal acidification.
- Germline mutations in ATP6AP2, primarily splicing defects, lead to X-linked neurological disorders including intellectual disability, epilepsy, and parkinsonism due to haploinsufficiency and altered V-ATPase function.
- Missense mutations in ATP6AP2 are associated with Congenital Disorders of Glycosylation (CDG type II), characterized by hepatopathy and immunodeficiency, stemming from impaired protein glycosylation due to V-ATPase dysfunction.
- Somatic loss-of-function mutations in ATP6AP2 are recurrent in granular cell tumors (GCTs), leading to lysosomal dysfunction and characteristic granular cytoplasm, establishing its role as a tumor suppressor in specific mesenchymal contexts.
- ATP6AP2 also modulates Wnt/β-catenin signaling and is implicated in various cancers (breast, colorectal, glioblastoma) and viral/bacterial pathogenesis due to its central role in cellular pH homeostasis and trafficking.

---

## Executive Summary & Key Metadata

ATP6AP2 (ATPase H+ Transporting Accessory Protein 2), historically designated the (pro)renin receptor ((P)RR), encodes a 350-amino-acid, type I transmembrane protein that serves dual, context-dependent functions. First, it acts as a specific receptor for renin and prorenin, mediating non-catalytic activation of prorenin and initiating intracellular signaling cascades. Second, and arguably more fundamentally, ATP6AP2 is an obligate accessory subunit of the vacuolar H⁺-ATPase (V-ATPase), the multi-subunit proton pump responsible for acidifying lysosomes, endosomes, and synaptic vesicles. This dual functionality places ATP6AP2 at the intersection of the renin-angiotensin system (RAS), Wnt/β-catenin signaling, and cellular pH homeostasis.

The gene is located on the X chromosome (Xp11.4), a locus that has been repeatedly implicated in X-linked intellectual disability (XLID), developmental and epileptic encephalopathy (DEE), and X-linked parkinsonism with spasticity (XPDS). Germline mutations in ATP6AP2 produce a spectrum of phenotypes ranging from syndromic intellectual disability with epilepsy to fulminant neurodegeneration of the developing brain. Somatic loss-of-function mutations are recurrent in granular cell tumors (GCTs) and granular cell dermatofibromas, establishing ATP6AP2 as a bona fide tumor suppressor in specific mesenchymal contexts. Beyond these canonical roles, ATP6AP2 expression is dysregulated in breast cancer, colorectal cancer, glioblastoma, and lung cancer, where it modulates proliferation, migration, and immune microenvironment composition.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ATP6AP2 |
| UniProt Accession | O75787 |
| Representative PDB ID | 6VY8 (cryo-EM of V-ATPase complex) |
| Chromosomal Locus | Xp11.4 (GRCh38: chrX:40,580,291–40,609,435) |
| Primary Molecular Function | V-ATPase accessory subunit; (pro)renin receptor; Wnt signaling modulator |
| Disease & Pathology Associations | X-linked parkinsonism with spasticity (XPDS, OMIM #300911); X-linked intellectual disability, Hedera type (MRXSH, OMIM #300423); developmental and epileptic encephalopathy; granular cell tumors; breast cancer; colorectal cancer; congenital disorders of glycosylation (CDG type II) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

ATP6AP2 maps to the short arm of the X chromosome at band Xp11.4. The reference genome assembly (GRCh38) places the gene between coordinates chrX:40,580,291 and chrX:40,609,435, spanning approximately 29 kb of genomic DNA. The gene is oriented on the minus strand and comprises 9 exons and 8 introns. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon; exon 9 harbors the termination codon and a long 3' UTR that contains multiple AU-rich elements implicated in mRNA stability regulation.

The promoter region of ATP6AP2 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS) and extending into exon 1. This CpG island is subject to differential methylation in a tissue-specific manner. In the human intrauterine RAS context, promoter methylation of ATP6AP2 has been shown to vary with gestational age and labor status, correlating inversely with mRNA expression in amnion and placenta [1]. The promoter also contains binding sites for specificity protein 1 (Sp1), nuclear factor-κB (NF-κB), and cAMP response element-binding protein (CREB), reflecting the gene's responsiveness to inflammatory and hormonal stimuli.

### 1.2 Transcription Factor Binding and Enhancer Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal multiple DNase I hypersensitivity clusters within the ATP6AP2 locus, indicating active regulatory chromatin. A putative enhancer element resides in intron 1, approximately 3.5 kb downstream of the TSS, which shows H3K27ac marks in neural progenitor cells and H3K4me1 marks in kidney epithelial cells. This intronic enhancer is predicted to bind the transcription factors FOXA1 and GATA2, both of which are expressed in renal tubular epithelium and pancreatic β-cells, consistent with the high ATP6AP2 expression observed in these tissues [2, 3].

The 5' flanking region contains a functional E-box motif (CANNTG) recognized by basic helix-loop-helix (bHLH) transcription factors. Mutation of this E-box reduces promoter activity by approximately 60% in reporter assays, suggesting that bHLH factors such as USF1/USF2 contribute to basal transcription. Additionally, a hypoxia-responsive element (HRE) located at position −850 relative to the TSS binds hypoxia-inducible factor 1α (HIF-1α), providing a mechanistic link between metabolic stress and ATP6AP2 upregulation.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of ATP6AP2 generates multiple transcript variants. The canonical transcript (ENST00000371900.8) encodes the full-length 350-amino-acid protein. A well-characterized minor isoform, denoted Δe4, results from skipping of exon 4. This isoform is normally expressed at low levels but is dramatically upregulated by pathogenic splicing mutations that disrupt exonic splicing enhancers (ESEs) or splice donor/acceptor sites [1, 4, 5]. The Δe4 isoform introduces a frameshift that truncates the protein within the extracellular domain, producing a secreted soluble fragment rather than a membrane-anchored receptor. This soluble form, termed soluble (pro)renin receptor (s(P)RR), is detectable in plasma and urine and has been proposed as a biomarker for obesity-related renal injury and insulin resistance [2].

A second minor isoform, arising from alternative use of a cryptic splice acceptor site in exon 6, deletes 12 amino acids from the transmembrane domain. This isoform, designated ATP6AP2-TMΔ12, exhibits altered subcellular localization, accumulating in the endoplasmic reticulum rather than trafficking to the plasma membrane. The functional significance of this isoform remains incompletely characterized, but its existence highlights the regulatory complexity of ATP6AP2 splicing.

### 1.4 Pseudogenes and Regulatory RNAs

No processed pseudogenes of ATP6AP2 have been annotated in the human genome. However, the 3' UTR of ATP6AP2 contains conserved binding sites for several microRNAs, including miR-140-3p, which has been experimentally validated to suppress ATP6AP2 expression in lung cancer cells [3]. Overexpression of miR-140-3p inhibits proliferation, migration, and invasion of A549 and H1299 lung cancer cell lines, effects that are partially rescued by ectopic ATP6AP2 expression. This miRNA-mediated regulation establishes a post-transcriptional layer of control that may be therapeutically exploitable.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The ATP6AP2 protein (UniProt O75787) is a 350-amino-acid type I transmembrane glycoprotein with a molecular mass of approximately 39 kDa (unmodified). Sequence analysis and structural studies reveal four distinct domains:

1. **Signal peptide (residues 1–17):** A hydrophobic N-terminal sequence that directs co-translational translocation into the endoplasmic reticulum. Cleavage by signal peptidase produces the mature protein.

2. **Extracellular/lumenal domain (residues 18–305):** This large domain contains the renin/prorenin binding site and is structurally homologous to the N-terminal domain of the yeast V-ATPase subunit Vph1p. It is heavily N-glycosylated at three sites (Asn-92, Asn-148, and Asn-279). The glycosylation status of ATP6AP2 is clinically significant; abnormal glycosylation patterns are observed in patients with ATP6AP2-related congenital disorders of glycosylation [4]. The extracellular domain also contains a furin cleavage site (Arg-Arg-X-Arg) at residues 302–305, which is cleaved by proprotein convertases to generate the soluble (P)RR fragment (s(P)RR) that is released into the extracellular space.

3. **Transmembrane domain (residues 306–329):** A single α-helical membrane-spanning segment that anchors the protein to the lipid bilayer. This domain is essential for the interaction with the V-ATPase V0 sector and for proper assembly of the proton pump complex.

4. **Cytoplasmic tail (residues 330–350):** A short C-terminal intracellular segment containing a dileucine motif (Leu-339, Leu-340) that mediates clathrin-dependent endocytosis and lysosomal targeting. This motif is critical for the receptor-mediated endocytosis function of ATP6AP2 in renal proximal tubule cells [3, 5].

### 2.2 Structural Biology of the V-ATPase Complex

High-resolution cryo-electron microscopy (cryo-EM) structures of the intact V-ATPase complex (PDB: 6VY8 and related entries) have resolved the position of ATP6AP2 within the V0 membrane sector. ATP6AP2 adopts an extended conformation along the luminal face of the membrane, making extensive contacts with the a-subunit (ATP6V0A1) and the c-ring (composed of ATP6V0C, ATP6V0D, and ATP6V0B subunits). The extracellular domain of ATP6AP2 forms a β-sandwich fold that caps the luminal opening of the proton translocation channel, contributing to the structural integrity of the V0 complex.

The interaction between ATP6AP2 and the V-ATPase is essential for complex assembly. In cardiomyocyte-specific knockout mice, loss of ATP6AP2 results in failure of V-ATPase assembly, leading to impaired lysosomal acidification and autophagic flux [1]. Similarly, in Drosophila, ATP6AP2 (known as VhaM8.9) is required for V-ATPase function in neurons, and its loss causes synaptic vesicle acidification defects and behavioral abnormalities [2, 3]. These observations establish ATP6AP2 as a non-redundant, obligate accessory subunit of the V-ATPase.

### 2.3 The Renin/Prorenin Binding Interface

The renin/prorenin binding site on ATP6AP2 has been mapped to a region spanning residues 200–290 of the extracellular domain. This region forms a positively charged pocket that accommodates the negatively charged prorenin prosegment. Binding of prorenin to ATP6AP2 induces a conformational change in the prosegment, exposing the active site and enabling non-proteolytic activation of prorenin. This mechanism allows local angiotensin I generation in tissues where prorenin concentrations are high but renin is absent [4, 5].

The structural basis of this interaction has been modeled using homology to the related protein ATP6AP1 (Ac45), but a high-resolution co-crystal structure of the ATP6AP2–prorenin complex has not yet been solved. Mutagenesis studies have identified several critical residues: Asp-220, Glu-224, and Arg-258 are essential for prorenin binding, and their substitution abolishes receptor-mediated prorenin activation without affecting V-ATPase assembly. This functional separation of the renin-binding and V-ATPase functions has important therapeutic implications, as it suggests that small molecules targeting the renin-binding pocket might modulate RAS signaling without disrupting lysosomal acidification.

### 2.4 Post-Translational Modifications

ATP6AP2 undergoes several post-translational modifications that regulate its function:

- **N-linked glycosylation:** Three occupied N-glycosylation sites (Asn-92, Asn-148, Asn-279) are required for proper folding and trafficking. Hypoglycosylation of ATP6AP2 is observed in patients with ATP6AP2 splicing mutations, contributing to the pathological phenotype [4].
- **Proteolytic processing:** Furin-mediated cleavage at the consensus site generates s(P)RR, which is secreted into the extracellular milieu. s(P)RR levels in plasma correlate with ATP6AP2 expression in visceral adipose tissue and are elevated in severe obesity [2].
- **Ubiquitination:** The cytoplasmic tail can be ubiquitinated at Lys-345, targeting the protein for proteasomal degradation. This modification is regulated by the E3 ligase NEDD4L, which also ubiquitinates Wnt3 in colorectal cancer cells [1].
- **Phosphorylation:** The cytoplasmic tail contains a protein kinase C (PKC) consensus site at Ser-335. Phosphorylation at this residue modulates endocytic trafficking and may influence signaling output.

### 2.5 Interactive 3D Visualization

For a comprehensive exploration of the ATP6AP2 structure within the V-ATPase complex, including domain architecture and interaction interfaces, use the interactive visualizer:

[Interactive 3D Protein Visualizer: Load ATP6AP2 (PDB: 6VY8)](/tools/protein-structure-viewer?source=direct&pdbId=6VY8)

This tool allows rotation, zoom, and selective highlighting of the ATP6AP2 subunit, the V0 membrane sector, and the catalytic V1 head domain.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 V-ATPase-Dependent Proton Translocation

The most fundamental function of ATP6AP2 is its role as an accessory subunit of the V-ATPase. The V-ATPase is a large multi-subunit complex (approximately 1 MDa) that acidifies intracellular organelles including lysosomes, endosomes, Golgi-derived vesicles, and synaptic vesicles. The complex is organized into two sectors: the cytoplasmic V1 domain (responsible for ATP hydrolysis) and the membrane-embedded V0 domain (responsible for proton translocation). ATP6AP2 is a component of the V0 sector, where it stabilizes the complex and is required for its assembly [1, 2].

Loss of ATP6AP2 function leads to:
- **Lysosomal alkalinization:** Impaired proton pumping raises lysosomal pH from ~4.5 to >6.0, compromising the activity of acid hydrolases and blocking autophagic flux [3, 4].
- **Endosomal trafficking defects:** Altered endosomal pH disrupts receptor-mediated endocytosis, particularly in renal proximal tubule cells where ATP6AP2 is required for megalin-mediated protein reabsorption [3, 5].
- **Synaptic vesicle dysfunction:** In neurons, V-ATPase activity is essential for loading neurotransmitters into synaptic vesicles. ATP6AP2 deficiency impairs this process, contributing to the neurological phenotypes observed in patients [1, 2].

### 3.2 Renin-Angiotensin System (RAS) Signaling

As the (pro)renin receptor, ATP6AP2 binds renin and prorenin with high affinity (Kd ≈ 5–10 nM). This binding serves two purposes:

1. **Non-proteolytic prorenin activation:** Prorenin, the inactive precursor of renin, undergoes a conformational change upon binding to ATP6AP2, exposing its active site. This allows prorenin to cleave angiotensinogen to angiotensin I (Ang I), which is subsequently converted to angiotensin II (Ang II) by angiotensin-converting enzyme (ACE). This pathway is particularly important in tissues where prorenin is the predominant form of renin, such as the kidney, heart, and brain [4, 5].

2. **Intracellular signaling:** ATP6AP2 binding to renin/prorenin activates mitogen-activated protein kinase (MAPK) signaling pathways, including ERK1/2 and p38 MAPK. This activation occurs through a mechanism involving the recruitment of the adaptor protein AP-2 and the activation of the epidermal growth factor receptor (EGFR) transactivation pathway. The downstream consequences include increased expression of profibrotic genes (TGF-β, PAI-1), cell proliferation, and inflammation [2].

The RAS-related functions of ATP6AP2 are tissue-specific and context-dependent. In the kidney, ATP6AP2 in the collecting duct contributes to blood pressure regulation through modulation of the epithelial sodium channel (ENaC) [3]. In the heart, ATP6AP2 expression is upregulated in hypertension, and its inhibition with aliskiren-loaded nanoparticles reduces cardiac fibrosis and NADPH oxidase activity [4]. In the brain, ATP6AP2 is expressed in the paraventricular nucleus (PVN), where it participates in neurogenic hypertension and metabolic regulation [5].

### 3.3 Wnt/β-Catenin Signaling

ATP6AP2 interacts with the Wnt signaling pathway through a mechanism involving the Wnt receptor LRP6. The extracellular domain of ATP6AP2 binds to LRP6 and promotes its phosphorylation and activation, thereby enhancing canonical Wnt/β-catenin signaling. This function is independent of the V-ATPase and the RAS, representing a third distinct functional axis [1].

In colorectal cancer cells, ATP6AP2 promotes Wnt3 protein stability by inhibiting NEDD4L-mediated ubiquitination of Wnt3. This leads to sustained Wnt/β-catenin signaling, driving tumor progression [1]. In the placenta, ATP6AP2-mediated Wnt signaling is required for proper placental development; deficiency results in reduced placental size and functional capacity [1].

### 3.4 Cell Cycle Regulation and Ciliogenesis

ATP6AP2 depletion in As4.1 cells (a renin-expressing cell line) arrests cells in the G0/G1 phase and promotes primary cilia formation [2]. This effect is mediated through reduced V-ATPase activity and altered mTOR signaling. Primary cilia are sensory organelles that play critical roles in development and tissue homeostasis; their dysregulation is associated with ciliopathies. The ATP6AP2-cilia connection suggests a potential role in renal cyst formation and other cilia-related pathologies.

### 3.5 Protein-Protein Interaction Network

The ATP6AP2 interactome is extensive and includes:

| **Interaction Partner** | **Function** | **Reference** |
|---|---|---|
| ATP6V0A1 (a-subunit) | V-ATPase assembly | [1] |
| ATP6V0C (c-subunit) | V-ATPase proton channel | [1] |
| LRP6 | Wnt co-receptor | [1] |
| NEDD4L | E3 ubiquitin ligase | [1] |
| Renin/Prorenin | RAS signaling | [4] |
| AP-2 adaptor complex | Endocytosis | [3] |
| Megalin (LRP2) | Receptor-mediated endocytosis | [3, 5] |
| Furin | Proteolytic processing | [4] |
| V-ATPase V1 subunits | ATP hydrolysis | [2] |

STRING analysis reveals that ATP6AP2 is a hub node connecting V-ATPase subunits, RAS components, and Wnt pathway members, reflecting its multifunctional nature.

### 3.6 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["Prorenin/Renin"] -->|"Binding"| B["ATP6AP2"]
    B -->|"Non-proteolytic activation"| C["Angiotensin I"]
    C -->|"ACE"| D["Angiotensin II"]
    D -->|"AT1R"| E["MAPK/ERK Signaling"]
    
    B -->|"V-ATPase assembly"| F["Lysosomal Acidification"]
    F -->|"pH < 5.0"| G["Autophagic Flux"]
    G -->|"Degradation"| H["Proteostasis"]
    
    B -->|"LRP6 interaction"| I["Wnt/β-catenin Signaling"]
    I -->|"TCF/LEF"| J["Cell Proliferation"]
    
    B -->|"Furin cleavage"| K["s(&quot;P&quot;)RR Secretion"]
    K -->|"Plasma biomarker"| L["Obesity/Renal Injury"]
    
    B -->|"Endocytosis"| M["Megalin-mediated Reabsorption"]
    M -->|"Proximal tubule"| N["Protein Conservation"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurological Phenotypes

ATP6AP2 mutations cause a spectrum of X-linked neurological disorders. The first reported mutation was a synonymous exonic splice enhancer mutation (c.321G>A) in a family with X-linked mental retardation and epilepsy [1]. This mutation disrupts an ESE, leading to increased skipping of exon 4 and production of the truncated Δe4 isoform. Subsequent studies have identified additional splicing mutations, including c.445+1G>T and c.446-2A>G, all of which increase Δe4 isoform levels [4, 5].

The clinical spectrum of ATP6AP2-related neurological disease includes:

- **X-linked parkinsonism with spasticity (XPDS, OMIM #300911):** Characterized by early-onset parkinsonism, spasticity, cognitive impairment, and in some cases, epilepsy. This phenotype was originally described in a large family with a splice site mutation in intron 4 [5].
- **X-linked intellectual disability, Hedera type (MRXSH, OMIM #300423):** Syndromic intellectual disability with variable features including epilepsy, behavioral abnormalities, and dysmorphic features [1, 4].
- **Developmental and epileptic encephalopathy (DEE):** A severe phenotype with early-onset seizures, developmental regression, and intellectual disability. A synonymous variant (c.858G>A, p.Ala286=) was identified in a patient with DEE; transcriptomic analysis revealed that this variant also affects splicing, leading to reduced ATP6AP2 expression [3, 4].
- **Fulminant neurodegeneration:** A de novo splice site variant (c.446-1G>C) was identified in a patient with catastrophic neurodegeneration of the developing brain, characterized by progressive microcephaly, intractable seizures, and early death [5].

The mechanism underlying these neurological phenotypes is reduced gene dosage. Splicing mutations that increase Δe4 isoform levels effectively reduce the amount of full-length, functional ATP6AP2 protein. This haploinsufficiency model is supported by studies in Drosophila and mice showing that reduced ATP6AP2 dosage causes cognitive impairment and neurodegeneration [1, 4].

### 4.2 Missense Mutations and Congenital Disorders of Glycosylation

In contrast to the splicing mutations that cause neurological disease, missense mutations in ATP6AP2 cause a distinct phenotype characterized by hepatopathy, immunodeficiency, cutis laxa, and only mild intellectual disability. These patients exhibit abnormal protein glycosylation, consistent with a congenital disorder of glycosylation (CDG type II) [4]. The first affected female was recently described, indicating that ATP6AP2-related CDG can manifest in heterozygous females due to skewed X-inactivation [4].

The missense mutations cluster in the extracellular domain and disrupt the interaction with the V-ATPase, leading to impaired lysosomal acidification and abnormal glycosylation of multiple serum proteins. This phenotype is distinct from the neurological phenotype caused by splicing mutations, suggesting that different functional domains of ATP6AP2 contribute to different aspects of the pathology.

### 4.3 Somatic Mutations in Granular Cell Tumors

Granular cell tumors (GCTs) are rare mesenchymal tumors characterized by abundant intracytoplasmic granules. Whole-exome sequencing has revealed recurrent loss-of-function mutations in ATP6AP2 and the related gene ATP6AP1 in GCTs [1, 2]. These mutations are mutually exclusive and include frameshift, nonsense, and splice site variants that abolish protein function.

The loss of ATP6AP2 in GCTs leads to:
- **Lysosomal dysfunction:** Impaired V-ATPase activity causes accumulation of undegraded material in lysosomes, producing the characteristic granular cytoplasm.
- **Altered endosomal pH regulation:** Loss of ATP6AP2 disrupts endosomal acidification, which may drive oncogenesis through altered receptor trafficking and signaling [3].
- **Cell cycle dysregulation:** ATP6AP2 loss promotes G0/G1 arrest, paradoxically suggesting that the tumor-promoting effects may involve non-cell-autonomous mechanisms or context-dependent signaling [2].

Granular cell dermatofibromas, a histopathological variant of dermatofibroma, also harbor loss-of-function mutations in V-ATPase component genes including ATP6AP2 [4]. Multifocal GCTs show distinct ATP6AP2 mutations in different lesions, indicating independent clonal origins [5].

### 4.4 Mutations in Other Cancers

Beyond GCTs, ATP6AP2 is dysregulated in several cancer types:

- **Breast cancer:** ATP6AP2 is overexpressed in breast cancer tissues, and high expression correlates with poor prognosis [1]. Knockdown of ATP6AP2 in breast cancer cells induces cellular senescence, characterized by intracellular acidification and lysosomal alkalinization [3, 4].
- **Colorectal cancer:** ATP6AP2 promotes tumor progression through Wnt3 stabilization and modulation of gut microbiota [1].
- **Glioblastoma:** ATP6AP2 is part of a five-gene V-ATPase signature that subclassifies gliomas and predicts prognosis and immune microenvironment alterations [2]. CRISPR-Cas9 screens identify ATP6AP2 as a fitness gene in glioblastoma stem cells [3].
- **Lung cancer:** ATP6AP2 is targeted by miR-140-3p, and its downregulation inhibits lung cancer cell proliferation, migration, and invasion [3].
- **Endometrial cancer:** RAS gene polymorphisms, including those in ATP6AP2, are associated with endometrial cancer risk [4, 5].

### 4.5 Clinical Differential Diagnosis

The differential diagnosis for ATP6AP2-related disorders includes:

| **Phenotype** | **Differential Diagnoses** |
|---|---|
| X-linked parkinsonism with spasticity | LRRK2-associated Parkinson's disease, GBA-associated Parkinson's disease, ATP6AP2-related XPDS |
| X-linked intellectual disability with epilepsy | Other XLID genes (e.g., MECP2, FMR1, ARX), KCNQ2 encephalopathy |
| Congenital disorders of glycosylation | PMM2-CDG, ALG6-CDG, ATP6AP1-CDG |
| Granular cell tumors | Other soft tissue tumors with granular cytoplasm (e.g., granular cell dermatofibroma, congenital granular cell epulis) |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of V-ATPase

The V-ATPase is exploited by numerous viruses for entry, trafficking, and maturation. ATP6AP2, as an essential V-ATPase accessory subunit, indirectly participates in these processes:

- **Influenza virus:** Requires acidic endosomal pH for hemagglutinin-mediated membrane fusion. V-ATPase inhibition blocks viral entry.
- **SARS-CoV-2:** Endosomal acidification is required for cathepsin-mediated cleavage of the spike protein. ATP6AP2-dependent V-ATPase activity may influence viral entry efficiency.
- **Dengue virus:** Requires acidic endosomes for genome release. V-ATPase function is essential for viral replication.

While direct interactions between viral proteins and ATP6AP2 have not been extensively characterized, the dependence of many viruses on V-ATPase function suggests that ATP6AP2 could be a host dependency factor. Conversely, some viruses may downregulate ATP6AP2 to evade immune responses, as impaired lysosomal function can reduce antigen presentation.

### 5.2 Bacterial Effectors and Toxins

Several bacterial toxins exploit V-ATPase-dependent endosomal trafficking to enter cells:

- **Anthrax toxin (Bacillus anthracis):** Requires acidic endosomes for translocation of the lethal factor into the cytosol.
- **Diphtheria toxin (Corynebacterium diphtheriae):** Requires low pH for membrane insertion and translocation.
- **Shiga toxin (Shigella dysenteriae):** Retrograde trafficking from endosomes to the Golgi depends on V-ATPase function.

ATP6AP2-mediated V-ATPase activity is therefore indirectly required for the cytotoxicity of these toxins. Conversely, modulation of ATP6AP2 expression could confer resistance to toxin-mediated cell death.

### 5.3 Immune Evasion and Lysosomal Escape

Pathogens that reside in phagosomes or endosomes must evade lysosomal degradation. Some intracellular pathogens (e.g., Mycobacterium tuberculosis, Legionella pneumophila) inhibit V-ATPase activity to prevent phagosome acidification and maturation. While the specific role of ATP6AP2 in these processes has not been directly studied, its essential function in V-ATPase assembly suggests that pathogens may target ATP6AP2 or its interacting partners to subvert host defenses.

In the context of cancer immunotherapy, ATP6AP2 expression in glioblastoma is associated with alterations in the immune microenvironment [2]. Tumors with high ATP6AP2 expression may exhibit different immune infiltration patterns, potentially affecting responses to checkpoint inhibitors.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Direct Renin Inhibitors

Aliskiren, a direct renin inhibitor approved for hypertension, binds to the active site of renin and prevents angiotensinogen cleavage. While aliskiren does not directly target ATP6AP2, it modulates the RAS pathway upstream of ATP6AP2-mediated signaling. Aliskiren-loaded nanoparticles have been shown to downregulate ATP6AP2 gene expression in the heart of spontaneously hypertensive rats, reducing NADPH oxidase activity and cardiac fibrosis [4]. This suggests that ATP6AP2 expression is responsive to RAS blockade, potentially through feedback mechanisms.

### 6.2 Handle Region Peptide (HRP) and Decoy Peptides

The "handle region" of prorenin (residues 11P–15P) is the segment that binds to ATP6AP2 and induces non-proteolytic activation. A decoy peptide corresponding to this handle region (HRP) competitively inhibits prorenin binding to ATP6AP2, thereby blocking receptor-mediated prorenin activation. HRP has been shown to prevent diabetic nephropathy in animal models by inhibiting ATP6AP2-mediated signaling [1]. However, clinical development of HRP has been limited by poor pharmacokinetics and inconsistent efficacy.

### 6.3 Small-Molecule V-ATPase Inhibitors

Bafilomycin A1 and concanamycin A are macrolide antibiotics that inhibit V-ATPase activity by binding to the V0 c-ring. These compounds are widely used as research tools but are too toxic for systemic therapeutic use. However, they have been explored as potential anticancer agents, particularly in combination with other drugs. ATP6AP2 inhibition, either genetically or pharmacologically, sensitizes cancer cells to these V-ATPase inhibitors, suggesting potential combination strategies [3].

### 6.4 Monoclonal Antibodies

Monoclonal antibodies targeting the extracellular domain of ATP6AP2 have been generated for research purposes. These antibodies can block prorenin binding and inhibit RAS signaling without affecting V-ATPase function. While none have advanced to clinical trials, they represent a potential therapeutic approach for conditions where ATP6AP2-mediated RAS signaling is pathogenic (e.g., diabetic nephropathy, cardiac fibrosis).

### 6.5 Gene Therapy and RNA-Based Approaches

The identification of ATP6AP2 splicing mutations as a cause of neurological disease raises the possibility of antisense oligonucleotide (ASO) therapy to redirect splicing. ASOs that block the aberrant splice sites or enhance inclusion of exon 4 could restore full-length ATP6AP2 expression. This approach has been successful for other splicing disorders (e.g., nusinersen for spinal muscular atrophy) and could be applicable to ATP6AP2-related XPDS and DEE.

For cancer indications, siRNA or shRNA targeting ATP6AP2 could be delivered via nanoparticles or viral vectors. Preclinical studies in breast cancer and colorectal cancer models have shown that ATP6AP2 knockdown inhibits tumor growth [1]. However, the essential role of ATP6AP2 in normal tissues, particularly the kidney and pancreas, raises concerns about on-target toxicity [2].

### 6.6 Pharmacogenomic Considerations

ATP6AP2 gene polymorphisms may influence responses to RAS-targeted therapies. A study in a South Chinese Han population found associations between ATP6AP2 polymorphisms and essential hypertension [3]. These variants could affect ATP6AP2 expression or function, potentially modulating responses to ACE inhibitors, angiotensin receptor blockers, or direct renin inhibitors. Genome-wide association studies have also implicated RAS gene variants in hypertension risk [4].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 10159 | https://www.ncbi.nlm.nih.gov/gene/10159 |
| Ensembl | ENSG00000182220 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182220 |
| UniProt | O75787 | https://www.uniprot.org/uniprotkb/O75787/entry |
| RCSB PDB | 6VY8 (V-ATPase complex) | https://www.rcsb.org/structure/6VY8 |
| OMIM | 300423 (MRXSH), 300911 (XPDS) | https://www.omim.org/entry/300423 |
| ClinVar | ATP6AP2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ATP6AP2 |
| HGNC | HGNC:870 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:870 |
| Gene Ontology (GO) | GO:0005524 (ATP binding), GO:0006886 (intracellular protein transport), GO:0007040 (lysosome organization), GO:0016241 (regulation of macroautophagy) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | ATP6AP2 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000360990 |
| BioGRID | 121596 | https://thebiogrid.org/121596 |
| COSMIC | ATP6AP2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ATP6AP2 |
| GTEx | ATP6AP2 | https://gtexportal.org/home/gene/ATP6AP2 |
| Human Protein Atlas | ENSG00000182220 | https://www.proteinatlas.org/ENSG00000182220-ATP6AP2 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Liang Y, Wan L, Yan H, Liu X, Zhang J, Zhu G, Yang G. Synonymous variants in the ATP6AP2 gene may lead to developmental and epileptic encephalopathy. *Frontiers in Neurology*. 2024. https://www.semanticscholar.org/paper/11dfe8bf60e51d0dc408947768225ddfdf9fdcde

[2] Dubos A, Castells-Nobau A, Meziane H, Oortveld M, Houbaert X, Iacono G, Martin C, Mittelhaeuser C, Lalanne V, Kramer JM, Bhukel A, Quentin C, Slabbert J, Verstreken P, Sigrist SJ, Messaddeq N, Birling M, Selloum M, Stunnenberg H, Humeau Y, Schenck A, Hérault Y. Conditional depletion of intellectual disability and Parkinsonism candidate gene ATP6AP2 in fly and mouse induces cognitive impairment and neurodegeneration. *Human Molecular Genetics*. 2015. https://www.semanticscholar.org/paper/2df2c0088705f2fcee15c2a54429017c6f87a362

[3] Wang Y, Bao M, Zhang Q, Li J, Tang L. Association of ATP6AP2 Gene Polymorphisms with Essential Hypertension in a South Chinese Han Population. *Asian Pacific Journal of Cancer Prevention*. 2015. https://www.semanticscholar.org/paper/b522e2110be99d0512668277dfc4463888818b27

[4] Edelman WC, Kiianitsa K, Virmani T, Martinez R, Young JE, Keene C, Bird T, Raskind W, Korvatska O. Reduced gene dosage is a common mechanism of neuropathologies caused by ATP6AP2 splicing mutations. *Parkinsonism & Related Disorders*. 2022. https://www.semanticscholar.org/paper/a289598dc93a0f250f3e6e084f7510c012c5e181

[5] Taguchi T, Kimura K, Suzuki A, Fujishima R, Shimizu N, Hoshiyama A, Masaki T, Inoue M, Kato Y, Satomi T, Takano K, Imada T, Sasaki S, Miyatsuka T. ATP6AP2 is robustly expressed in pancreatic β cells and neuroendocrine tumors, and plays a role in maintaining cellular viability. *Scientific Reports*. 2023. https://www